OncoMatch/Clinical Trials/NCT07314723
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Is NCT07314723 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including 9MW2821 and Toripalimab for urothelial carcinoma.
Treatment: 9MW2821 · Toripalimab — This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage T2-4AN0-1, T2-4AN0
Excluded: Stage IV
Imaging confirmed non-metastatic urothelial cancer (M0). Arm 1: MIBC, T2-4aN0-1. Arm 2: High-risk UTUC, N0. Arm 3: MIBC, T2-4aN0.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
Prior systemic anti-tumor therapy for urothelial cancer
Cannot have received: anti-PD-1/PD-L1 therapy
Previously treated with PD-1/PD-L1 inhibitors
Cannot have received: antibody-drug conjugate
Previously treated with...antibody-drug conjugates (ADCs)
Lab requirements
Blood counts
Adequate organ functions
Kidney function
Adequate organ functions
Liver function
Adequate organ functions
Adequate organ functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07314723 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T2-4AN0-1 or T2-4AN0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages